SecBot SecBot
SECBOTREPLAY Home › Report › OCUL

OCUL · Ocular Therapeutix announced FDA alignment to submit an NDA for AXPAXLI…

Ocular Therapeutix, Inc. · PRESS-RELEASE filed Jun 17, 2026 at 08:45 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 17, 2026 at 08:45 ET

Ocular Therapeutix announced FDA alignment to submit an NDA for AXPAXLI in wet AMD in Q4 2026 based on SOL-1 efficacy/safety data and interim SOL-R safety data, with potential for accelerated 505(b)(2) review. The company also streamlined its diabetic retinopathy program to a single registrational trial (HELIOS-3) evaluating Q12M dosing. Q1 2026 EPS of -$0.40 slightly missed consensus of -$0.39, but the regulatory catalyst dominates the narrative.

  • FDA alignment to submit AXPAXLI NDA for wet AMD in Q4 2026 under 505(b)(2) pathway, potentially accelerating review by up to 60 days.
  • NDA based on SOL-1 Week 52 data (primary endpoint met with p=0.0006) plus interim SOL-R safety analysis targeting >300 patients.
  • SOL-R efficacy data no longer part of NDA; trial extended to Week 96 with new superiority endpoint vs aflibercept 8mg (topline 1Q 2028).
  • Diabetic retinopathy program streamlined to HELIOS-3, a single registrational trial evaluating AXPAXLI Q12M vs sham (primary endpoint at Week 56).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access